You’ve Already Paid $6 Billion For Weight-Loss Drugs You Can’t Afford The Lever
Day: March 6, 2025
The Billion-Dollar Taxpayer Math Behind The Ozempic Boom – The Lever
The Billion-Dollar Taxpayer Math Behind The Ozempic Boom The Lever
Beyond compliance: The strategic role of PASS in rare disease therapy success
Post-authorisation safety studies (PASS) are often seen simply as a regulatory necessity, a checkbox that ensures…
Realising the opportunities for growth in the European orphan drug market
The European orphan drug market is growing and is already comparable in size and scope to…
Patients struggle with lack of consistent coverage for popular weight-loss drugs – Black Hills Pioneer
Patients struggle with lack of consistent coverage for popular weight-loss drugs Black Hills Pioneer
Orphan drugs: How to avoid costly stock losses in Europe
With orphan drugs typically being high value, the potential risk of stock losses should be a…
FDA approves ARS’ neffy 1mg for paediatric anaphylaxis
FDA has granted approval for ARS Pharmaceuticals’ neffy 1mg for treating anaphylaxis in paediatric patients.
Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast. – Barron’s
Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast. Barron’s
Trump Probes Long-Approved Meds; Could FDA Revoke Approvals? – Medscape
Trump Probes Long-Approved Meds; Could FDA Revoke Approvals? Medscape
Amgen Challenges Novo Nordisk’s Ozempic And Eli Lilly’s Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials – Benzinga
Amgen Challenges Novo Nordisk’s Ozempic And Eli Lilly’s Zepbound As Its Monthly Weight Loss Drug MariTide…